Diabetes Obesity & Metabolism

Article	Citations
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension	266
Proportion of newly diagnosed diabetes in COVID‐19 patients: A systematic review and meta‐analysis	200
Obesity as a multisystem disease: Trends in obesity rates and obesity‐related complications	183
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update	176
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity	169
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review	119
Prediabetes and the risk of heart failure: A meta‐analysis	107
Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis	98
Hybrid closed‐loop therapy: Where are we in 2021?	97
Comparison of MiniMed 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users	95
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes	93
Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study	76
A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know	68
Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials	67
Evidence‐based weight loss interventions: Individualized treatment options to maximize patient outcomes	66
Obesity as a risk factor for COVID‐19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart disease	66
Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials	66
The PREVIEW intervention study: Results from a 3‐year randomized 2 x 2 factorial multinational trial investigating the role of protein, glycaemic index and physical activity for prevention	66
Relationship between obesity and severe COVID‐19 outcomes in patients with type 2 diabetes: Results from the CORONADO study	65
Semaglutide for the treatment of overweight and obesity: A review	62
Association of obesity with postacute sequelae of COVID‐19	62
The dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc	61
Hybrid closed‐loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double‐blind, multicentre, multinational, randomized, crossover st	59
Association between prediabetes and adverse outcomes in heart failure	58
Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults	58

Predictors of time in target glucose range in real‐world users of the MiniMed 780G system	57
Global mortality of diabetic foot ulcer: A systematic review and meta‐analysis of observational studies	57
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, ran	56
Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta‐analysis	53
Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested posi	53
Understanding the clinical implications of differences between glucose management indicator and glycated haemoglobin	52
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications	52
Effectiveness and safety of sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in older adults with type 2 diabetes: A nationwide population‐based study	51
Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials	51
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective	51
Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, mul	49
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss	48
Effects of 6 weeks of treatment with dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo‐controlle	48
COVID‐19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission	47
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes	47
Sodium‐glucose cotransporter‐2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body‐induced NRF2 activation	47
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline cha	46
C‐peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective	45
Technology in the management of type 2 diabetes: Present status and future prospects	45
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes	45
New insights into the treatment of obesity	45
Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study	44
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial	44
Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes	44
Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study	43
Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study	43
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis	42
A phase 3 randomized clinical trial using a once‐weekly glucagon‐like peptide‐1 receptor agonist in adolescents and young adults with hypothalamic obesity	42
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses	42
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study	42
Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review	42
Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis	42
Effects of the COVID‐19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study	41
Real‐world performance of the MiniMed™ 670G system in Europe	40
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials	40
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease	40
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity	38
Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality	37
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial	37
Add‐on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study	37
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment	36
The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, doubl	36
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial	36
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phas	36
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus trea	35
An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight	35
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison	34
Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials	34
Risk of new‐onset type 2 diabetes in 600 055 people after COVID‐19: A cohort study	34
Benefits of continuous positive airway pressure on glycaemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnoea: A meta‐analysis	33

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study	33
IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomi	33
Metabolically healthy obesity and cardiovascular events: A nationwide cohort study	33
HbA1c and brain health across the entire glycaemic spectrum	32
Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized con	32
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide	32
Sodium‐glucose co‐transporter‐2 inhibitors and susceptibility to COVID‐19: A population‐based retrospective cohort study	32
Sodium‐glucose co‐transporter‐2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis	32
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double‐blind, phase 2 trial	32
A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes	31
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonistBI456906	31
Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial with a 36‐we	31
The J‐shaped relationship between body mass index and mortality in patients with COVID‐19: A dose‐response meta‐analysis	31
Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan	31
Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study	31
Metformin‐induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes	30
Validation of obesity‐related diagnosis codes in claims data	30
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes	30
Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study	29
Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2	28
Effects of a 6‐month, low‐carbohydrate diet on glycaemic control, body composition, and cardiovascular risk factors in patients with type 2 diabetes: An open‐label randomized controlled trial	28
Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review	28
Real‐world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed‐loop use	28
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with	27
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial	27
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment	27
The sodium‐glucose co‐transporter‐2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apop	27
Association of lactation with maternal risk of type 2 diabetes: A systematic review and meta‐analysis of observational studies	27
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus	27
Use of once‐weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study	27
Association between visit‐to‐visit HbA1c variability and the risk of cardiovascular disease in patients withtype 2diabetes	26
Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial	26
Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease	26
Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11):	26
Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11	26
Sotagliflozin for patients with type 2 diabetes: A systematic review and meta‐analysis	26
Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States	26
Current trends in diabetes mellitus database research in Japan	25
A real‐world study of user characteristics, safety and efficacy of open‐source closed‐loop systems and Medtronic 670G	25
Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms	25
Risk of diabetic macular oedema with sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes patients: A multi‐institutional cohort study in Taiwan	25
The impact of the COVID‐19 pandemic on glycaemic control in people with diabetes: A systematic review and meta‐analysis	25
Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis	25
Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence	24
Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes	24
Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes	24
Lower risk of hospitalization for heart failure, kidney disease and death with sodium‐glucose co‐transporter‐2 inhibitors compared with dipeptidyl peptidase‐4 inhibitors in type 2 diabetes regardless	23
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials	23
Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed‐loop insulin delivery system: A series of N‐of‐1 randomized controlled trials	23
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin‐treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial	23
Obesity as a driver of international differences in COVID‐19 death rates	23
Ultra‐rapid‐acting insulins for adults with diabetes: A systematic review and meta‐analysis	23
Real‐world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniM	23
Comparative efficacy and safety of glucose‐lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta‐analysis	22
Effectiveness of a closed‐loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: A prospective, multicentre, real‐life study	22
Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?	22
Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019	22
Metabolic surgery: A clinical update	22
Understanding the place for GLP‐1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection	22
Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants	22
Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon‐like peptide‐1 receptor agonists or sodium‐glucose cotransporter‐2 inhibitors: A real‐world study in two Ita	22
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial	22
Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials	22
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial	21
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020	21
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular and renal outcomes: A meta‐analysis and meta‐regression analysis	21
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add‐on to metformin in patients with type 2 diabetes	21
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electro	21
Efficacy and safety of 28‐day treatment with oral insulin (ORMD‐0801) in patients with type 2 diabetes: A randomized, placebo‐controlled trial	21
Very low carbohydrate (ketogenic) diets in type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials	21
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies	21
Reducing the need for carbohydrate counting in type 1 diabetes using closed‐loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non‐inferiority, crossove	20
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy	20
Changes in the use of glucose‐lowering drugs: A Danish nationwide study	20
Use of sodium‐glucose co‐transporter‐2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations	20
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events	20
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes	20
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes	20
The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial	20
Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS‐HFDM	20

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries	20
What is the value of faster acting prandial insulin? Focus on ultra rapid lispro	19
ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes	19
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase 3a clinical trial	19
Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial	19
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2	19
In‐home use of a hybrid closed loop achieves time‐in‐range targets in preschoolers and school children: Results from a randomized, controlled, crossover trial	19
Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose‐ranging study	19
Completion of annual diabetes care processes and mortality: A cohort study using the National Diabetes Audit for England and Wales	19
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment	18
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the ra	18
Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network	18
Combined therapy with CD4+CD25highCD127− T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Ra	18
Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J‐mono substudy)	18
Continuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head	18
Epicardial adipose tissue thickness is associated with reduced peak oxygen consumption and systolic reserve in patients with type 2 diabetes and normal heart function	18
Longevity of the novel ConvaTec infusion set with Lantern technology	18
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia	18
Effects of whey protein plus vitamin D supplementation combined with progressive resistance training on glycaemic control, body composition, muscle function and cardiometabolic risk factors in middle‐	18
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials	18
Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin‐treated adults with type 2 diabetes and risk factors for	17
Metformin versus insulin therapy for gestational diabetes: Effects on offspring anthropometrics and metabolism at the age of 9 years: A follow‐up study of two open‐label, randomized controlled trials	17
Dose‐dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by 18F‐labelled fluorodeoxyglucose positron emission tomography‐MRI	17
The glucose tolerance test in mice: Sex, drugs and protocol	17
Real‐world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias	17
Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data	17
Distribution patterns of intramyocellular and extramyocellular fat by magnetic resonance imaging in subjects with diabetes, prediabetes and normoglycaemic controls	17
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice	17
A global country‐level analysis of the relationship between obesity and COVID‐19 cases and mortality	17
Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials	17
Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease	17
Diabetogenic effects of cardioprotective drugs	17
Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week	17
Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States	17
Glucagon‐like peptide‐1 receptor agonists and risk of thyroid cancer: A systematic review and meta‐analysis of randomized controlled trials	17
MRI measures of hypothalamic injury are associated with glucagon‐like peptide‐1 receptor agonist treatment response in people with hypothalamic obesity	17
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes	17
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (	17
Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controll	17
Using machine learning to predict severe hypoglycaemia in hospital	17
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease	17
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications	17
An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg	16
Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea)	16
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor ag	16
Plasma proteome profiles treatment efficacy of incretin dual agonism in diet‐induced obese female and male mice	16
Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men	16
Effectiveness of low‐carbohydrate diets for long‐term weight loss in obese individuals: A meta‐analysis of randomized controlled trials	16
Dose‐dependent efficacy of the glucose‐dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3‐30)NH2 on GIP actions in humans	16
High‐dose sodium‐glucose co‐transporter‐2 inhibitors are superior in type 2 diabetes: A meta‐analysis of randomized clinical trials	16
Impact of the initial decline in estimated glomerular filtration rate on the risk of new‐onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated	16
Exendin(9‐39)NH2: Recommendations for clinical use based on a systematic literature review	16
Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke	16
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open‐label, noninferiority trial	16
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis	16
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND	16
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study	16
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes	16
Change in glucose‐lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID‐19 pandemic in Germany	16
Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID‐19 patients with diabetes: A population‐based study in Lombardy	16
Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A ran	15
The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin‐resistant adults: A randomized trial	15
Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial	15
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme	15
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents	15
Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da Qing Diabetes Prevention Outcome Study	15
Outcomes of hybrid closed‐loop insulin delivery activated 24/7 versus evening and night in free‐living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial	15
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled tri	15
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: Th	15
Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials	15
Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus	15
Effect of the glucagon‐like peptide‐1 analogue liraglutide versus placebo treatment on circulating proglucagon‐derived peptides that mediate improvements in body weight, insulin secretion and action:	15
Risk of developing diabetes in patients with atrial fibrillation taking non‐vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study	15
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults	15
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance	15
Sodium‐glucose co‐transporter‐2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta‐analysis	15
Clinical significance of prediabetes, undiagnosed diabetes and diagnosed diabetes on critical outcomes in COVID‐19: Integrative analysis from the JapanCOVID‐19 task force	15
Combined sodium glucose co‐transporter‐2 inhibitor and angiotensin‐converting enzyme inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a ra	15
The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study	15
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis	15
Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes	15
Risk of thyroid cancer associated with glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: A population‐based cohort study	15
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?	15
Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Programme	14
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future	14
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction	14
The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with	14
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis	14
Glucagon‐like peptide‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?	14
Metformin dose increase versus added linagliptin in non‐alcoholic fatty liver disease and type 2 diabetes: An analysis of the J‐LINK study	14
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide	14
Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial	14
A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study	14
Real‐world data of 12‐month adjunct sodium‐glucose co‐transporter‐2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c withou	14
Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial	14